153 related articles for article (PubMed ID: 38149251)
41. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.
Mehta RS; Saliba RM; Jan A; Shigle TL; Wang E; Nieto Y; Ciurea SO; Oran B; Im J; Olson A; Marin D; Qazilbash M; Khouri I; Rondon G; Anderlini P; Rezvani K; Popat U; Kebriaei P; Shpall E; Champlin R; Alousi A
Transplant Cell Ther; 2021 Mar; 27(3):272.e1-272.e5. PubMed ID: 33781539
[TBL] [Abstract][Full Text] [Related]
42. Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes.
El Jurdi N; Rayes A; MacMillan ML; Holtan SG; DeFor TE; Witte J; Arora M; Young JA; Weisdorf DJ
Blood Adv; 2021 Mar; 5(5):1352-1359. PubMed ID: 33656537
[TBL] [Abstract][Full Text] [Related]
43. Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo.
Malagola M; Cancelli V; Skert C; Leali PF; Ferrari E; Tiburzi A; Sala ML; Donnini I; Chiusolo P; Mussetti A; Battista M; Turra A; Cattina F; Rambaldi B; Schieppati F; Polverelli N; Bernardi S; Perucca S; Marini M; Laszlo D; Savignano C; Patriarca F; Corradini P; Piccirillo N; Sica S; Bosi A; Russo D
Transplantation; 2016 Dec; 100(12):e147-e155. PubMed ID: 27861297
[TBL] [Abstract][Full Text] [Related]
44. Feasibility of extracorporeal photopheresis in pediatric patients with graft-versus-host disease after hematopoietic stem cell transplantation.
Winther-Jørgensen S; Nygaard M; Heilmann C; Ifversen M; Sørensen K; Müller K; Masmas T
Pediatr Transplant; 2019 Jun; 23(4):e13416. PubMed ID: 30973668
[TBL] [Abstract][Full Text] [Related]
45. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
[TBL] [Abstract][Full Text] [Related]
46. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
Abedin SM; Hamadani M
Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
[TBL] [Abstract][Full Text] [Related]
47. Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience.
Calore E; Marson P; Pillon M; Tumino M; Tison T; Mainardi C; De Silvestro G; Rossin S; Franceschetto G; Carraro E; Pescarin M; Varotto S; Destro R; Gazzola MV; Basso G; Messina C
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1963-72. PubMed ID: 26183078
[TBL] [Abstract][Full Text] [Related]
48. Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials.
Luo C; Huang X; Wei L; Wu G; Huang Y; Ding Y; Huang Z; Chen J; Li X; Zou Y; Xu S
Front Immunol; 2023; 14():1211171. PubMed ID: 37409129
[TBL] [Abstract][Full Text] [Related]
49. Differential protein expression in endothelial cells exposed to serum from patients with acute graft-vs-host disease, depending on steroid response.
Martinez-Sanchez J; Palomo M; Pedraza A; Moreno-Castaño AB; Torramade-Moix S; Rovira M; Salas MQ; Cid J; Escolar G; Penack O; Carreras E; Diaz-Ricart M
J Cell Mol Med; 2023 May; 27(9):1227-1238. PubMed ID: 37016544
[TBL] [Abstract][Full Text] [Related]
50. Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients.
Grabner M; Strati E; Sandman K; Forsythe A
J Manag Care Spec Pharm; 2021 May; 27(5):607-614. PubMed ID: 33908282
[No Abstract] [Full Text] [Related]
51. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Jagasia M; Perales MA; Schroeder MA; Ali H; Shah NN; Chen YB; Fazal S; Dawkins FW; Arbushites MC; Tian C; Connelly-Smith L; Howell MD; Khoury HJ
Blood; 2020 May; 135(20):1739-1749. PubMed ID: 32160294
[TBL] [Abstract][Full Text] [Related]
52. Ruxolitinib combined with etanercept induce a rapid response to corticosteroid-refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi-center prospective study.
Zhao Y; Wu H; Shi J; Luo Y; Li X; Lan J; Ni W; Lu Y; Chen L; Tan Y; Lai X; Yu J; Huang H
Am J Hematol; 2020 Sep; 95(9):1075-1084. PubMed ID: 32510625
[TBL] [Abstract][Full Text] [Related]
53. Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD.
Zhang H; Chen R; Cheng J; Jin N; Chen B
Patient Prefer Adherence; 2015; 9():105-11. PubMed ID: 25653504
[TBL] [Abstract][Full Text] [Related]
54. Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Axt L; Naumann A; Toennies J; Haen SP; Vogel W; Schneidawind D; Wirths S; Moehle R; Faul C; Kanz L; Axt S; Bethge WA
Bone Marrow Transplant; 2019 Nov; 54(11):1805-1814. PubMed ID: 31089279
[TBL] [Abstract][Full Text] [Related]
55. Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study.
Berger M; Albiani R; Sini B; Fagioli F
Transfusion; 2015 Apr; 55(4):736-47. PubMed ID: 25355659
[TBL] [Abstract][Full Text] [Related]
56. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
[TBL] [Abstract][Full Text] [Related]
57. Shaping of CD56
Ni M; Wang L; Yang M; Neuber B; Sellner L; Hückelhoven-Krauss A; Schubert ML; Luft T; Hegenbart U; Schönland S; Wuchter P; Chen BA; Eckstein V; Krüger W; Yerushalmi R; Beider K; Nagler A; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
Front Immunol; 2019; 10():547. PubMed ID: 30949182
[TBL] [Abstract][Full Text] [Related]
58. Extracorporeal photopheresis: a useful therapy for patients with steroid-refractory acute graft-versus-host disease but not for the prevention of the chronic form.
Rubegni P; Feci L; Poggiali S; Marotta G; D'Ascenzo G; Murdaca F; Fimiani M
Br J Dermatol; 2013 Aug; 169(2):450-7. PubMed ID: 23534380
[TBL] [Abstract][Full Text] [Related]
59. Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes.
Herzog S; Weisdorf DJ; Shanley R; Rayes A; Holtan SG; Young JA; MacMillan ML; El Jurdi N
Blood Adv; 2023 Jul; 7(14):3644-3650. PubMed ID: 37036949
[TBL] [Abstract][Full Text] [Related]
60. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X
BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
